Disease · EFO_0004352
mortality
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. mortality. Diseases, record EFO_0004352. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004352
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs65
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ENOXAPARIN | CHEMBL1201685 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| SEVOFLURANE | CHEMBL1200694 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALANYL GLUTAMINE | CHEMBL3707366 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEMIPARIN | CHEMBL3707365 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CEFOTAXIME | CHEMBL1730 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEFTRIAXONE | CHEMBL161 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 65
See all 65 drugsTargets66
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 8 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 5 | Type-1 angiotensin II receptor antagonist | Unknown | https://conductscience.org/library/genes/185 | Drugs and targets |
| SERPINC1 | Antithrombin-III | 5 | Antithrombin-III activator | Phase 3 | https://conductscience.org/library/genes/462 | Drugs and targets |
| ADRB1 | Adrenergic receptor beta | 3 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist | Phase 1 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 3 | Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist | Phase 1 | https://conductscience.org/library/genes/154 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
1 to 10 of 66
See all 66 targetsTrials36
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03096314 | Vitamin D to Improve Outcomes by Leveraging Early Treatment | Phase 3 | 1,358 | 2020-01-27 | Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness | CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov |
| NCT02086500 | Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial) | Phase 3 | 903 | 2020-09-10 | Traumatic Hemorrhage | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT04411472 | (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI | Phase 3 | 676 | 2024-06-03 | Acute Kidney Injury Due to Sepsis | ILOFOTASE ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT00328094 | Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery | Not applicable | 242 | 2013-04-09 | Peripheral Vascular Disease, Abdominal Aortic Aneurysm | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT00248638 | Efficacy and Mechanisms of GLN Dipeptide in the SICU | Phase 3 | 150 | 2014-02-13 | Critical Illness | ALANYL GLUTAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT01349101 | A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | Phase 2 | 78 | 2025-12-15 | Hematological Malignancies | BUSULFAN, CYCLOPHOSPHAMIDE, FLUDARABINE, MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00487162 | The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality | Not applicable | 56 | 2014-04-03 | Hyperglycemia | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT00978419 | Pilot Trial of Statin Use in Burn Patients | Phase 2 | 40 | 2018-06-01 | Burns | ROSUVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02285153 | Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit | Phase 3 | 15 | 2019-12-18 | Critical Illness | ASPIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT07249164 | Dexmedetomidine Medication Records and Delirium After Coronary Artery Bypass Grafting | 343,112 | Delirium, Cardiac Surgical Procedures, Coronary Artery Bypass Graft (CABG), Valve Surgery, Postoperative Complications | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 36
See all 36 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| High Dose Vitamin D Formulation vs Placebo: serious adverse events | 14 of 690 | 18 of 668 | 1,358 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: deaths from any cause | 159 of 681 | 137 of 656 | 1,337 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: Hospital Mortality to Day 90 | 92 of 538 | 72 of 539 | 1,077 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: All-cause, All-location Mortality to Day 90 | 125 of 531 | 109 of 528 | 1,059 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: All-cause, All Location Mortality to Day 28 | 92 of 531 | 69 of 528 | 1,059 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: Alive and Home (Prior Level of Care) at Day 90 | 348 of 528 | 345 of 526 | 1,054 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: Hypercalcemia to Day 14 | 14 of 513 | 11 of 523 | 1,036 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: Falls to Day 90 | 36 of 507 | 27 of 507 | 1,014 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: Fall-related Fractures to Day 90 | 4 of 507 | 2 of 507 | 1,014 | NCT03096314 | Trial comparisons |
| High Dose Vitamin D Formulation vs Placebo: Kidney Stones to Day 90 | 0 of 507 | 3 of 507 | 1,014 | NCT03096314 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials60
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0004352
GET https://conductscience.org/api/diseases/v1/EFO_0004352/drugs?page=2